Study Summary
This trialwill study the safety and effectiveness of a drug in adults with moderate to severe AD, requiring visits every 4 weeks and if needed, home visits for administration of drug and assessment of vital signs.
- Atopic Dermatitis
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 23 Secondary · Reporting Duration: DRI17366 Baseline to Week 104
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Amlitelimab
1 of 1
Experimental Treatment
300 Total Participants · 1 Treatment Group
Primary Treatment: Amlitelimab · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are members of the public currently able to access this clinical experiment?
"Affirmative, the information hosted on clinicaltrials.gov displays that this study is presently enrolling patients. The medical trial was initially posted on August 22nd 2022 and has been recently revised as of November 29th 2022. 300 people are currently being sought from 3 different sites for participation in the research." - Anonymous Online Contributor
How many enrollees are being admitted to this research endeavor?
"Affirmative, clinicaltrials.gov states that this research project is currently engaging in recruitment efforts. It was posted on 8th August 2022 and modified most recently on 29th November 2022. It aims to source 300 participants from 3 different sites." - Anonymous Online Contributor
Has Amlitelimab been given regulatory authorization by the FDA?
"Our assessment at Power of Amlitelimab's safety is a 2 due to the lack of efficacy trials and only some data on its security." - Anonymous Online Contributor